Neurogene Inc (NGNE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $495.37M
Last updated: Nov 17, 2026 at 11:06 AM ET
Neurogene Inc (NGNE) Stock Forecast
Analysts expect Neurogene (NGNE) to earn -$4.98 per share in the fiscal year ending Dec 31, 2026. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.90, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 9 | 90.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$4.98
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$5.71
- EPS consensus
- Next report
- Mar 22, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$4.98 | -$5.04 to -$4.92 | 2 |
| Dec 31, 2027 | -$5.71 | -$7.72 to -$4.80 | 6 |
Quarterly Estimates
The EPS consensus rises from -$1.38 for the quarter ending Dec 31, 2026 to -$1.37 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.38 | -$1.61 to -$1.04 | 12 |
| Mar 31, 2027 | -$1.37 | -$1.73 to -$1.18 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 3 |
| Fiscal year ending Dec 31, 2027 | 3 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$5.66.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.98 | -$5.75 | -$5.75 | -$5.66 | -$5.66 | N/A |
| Fiscal year ending Dec 31, 2027 | -$5.71 | -$5.72 | -$5.69 | -$5.18 | -$5.18 | N/A |
| Quarter ending Mar 31, 2027 | -$1.37 | -$1.38 | -$1.38 | -$1.21 | -$1.21 | N/A |
Frequently Asked Questions About NGNE
What is the NGNE stock forecast?
Consensus analyst estimates put Neurogene's EPS at -$4.98 for the fiscal year ending Dec 31, 2026. The consensus rating from 10 analysts is Buy.
How do analysts rate NGNE stock?
Of 10 analysts covering Neurogene, 1 rates it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NGNE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.98, with estimates from -$5.04 to -$4.92 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$5.71, with estimates from -$7.72 to -$4.80 from 6 analysts.
How many analysts cover NGNE?
10 analysts rate Neurogene stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NGNE pages: Overview, Earnings, Forecast, Financials, Competitors